Cannabis causes euphoria and alters perception

The argument

The active compounds within cannabis are called cannabinoids, and their effects follow from the fact that the body already contains a system for them to act on. These compounds interact with and activate specific cannabinoid receptor molecules throughout the body, including in the brain and nervous system. Because those receptors are distributed widely rather than confined to one region, the effects of the drug appear across several functions at once rather than in a single isolated capacity, which is why perception and mood are altered together rather than separately. The euphoric effect is traced to one pathway in particular. Cannabinoids also increase the activity of dopamine in the brain's mesolimbic pathway, also known as the reward pathway. This is the circuit that ordinarily signals that something of value has happened, and raising dopamine activity within it can affect motivation, desire, and pleasure responses after consumption. The subjective experience of euphoria corresponds to a system that normally responds to events being activated chemically instead, which is the sense in which the drug produces the feeling directly rather than by supplying the user with something to feel good about. The same mechanism accounts for what happens over repeated use. Tolerance to the effects of cannabinoids increases as the receptors are activated again and again, so an unchanged quantity produces a diminishing effect. Prolonged use of cannabis can result in cognitive impairment and worsen the symptoms of mental illness. Those outcomes are not separate from the acute effects but the longer-term consequence of the same interaction between cannabinoids and the receptors they bind to, which is why an account of how cannabis acts on the nervous system has to cover both the immediate euphoria and what follows from repetition.

Premises

Counter-arguments

A counter notes that cannabis is not straightforwardly a depressant. Pharmacologists typically classify it separately as a cannabinoid, and its effects are mixed — depressant, stimulant and hallucinogenic — depending on dose, strain and individual. Raising dopamine in the brain's reward pathway is characteristic of rewarding and stimulant drugs generally, not specifically of depressants, so the mechanism the argument describes does not by itself locate cannabis among substances that 'slow' the nervous system. Placing it under 'depressants' is therefore a contested categorisation rather than a settled one, and the euphoria and altered perception it cites are as consistent with stimulant or hallucinogenic classification.

Rejecting the premises

[Rejecting P2] Increasing dopamine in the reward pathway is common to many drug classes, including stimulants, so it does not specifically identify cannabis as a depressant. [Rejecting C] Pharmacologists usually class cannabis as its own cannabinoid category with mixed depressant, stimulant and hallucinogenic effects, so slotting it solely under 'depressants' is a contested simplification.